Does a complete pathologic response to neoadjuvant chemotherapy affect the duration of endocrine therapy/OFS that you recommend for a premenopausal patient with HR+/Her2+ breast cancer?

This is a great question. In my practice, I do not alter duration of endocrine therapy based on response to chemo. Luminal tumors less commonly achieve pCR, and degree of response to neoadjuvant chemotherapy is less reliable as a prognostic factor in luminal tumors compared to TNBC and HER2+ tumors....